Grit Biotechnology

📍 Pudong New Area, Shanghai, China🗓 Founded 2019👥 8 employees💰 Last funded Aug 2023
Biotechnology🌐 grit-bio.com
Website LinkedIn
Grit Bio is a Chinese cell therapy company founded in 2019. The company is developing tumor-infiltrating lymphocyte (TIL) therapy program to address the unmet medical needs and to improve the quality of life for patients with solid tumor. GT101 - Grit’s non-gene-modified TIL product manufactured using proprietary process - is the first TIL product received Investigational New Drug (IND) approval in China and is currently in Phase 1 clinical trial. Grit Bio has established three core technology platforms for its TIL development: StaViral® - a retroviral system tailored for TIL engineering, ImmuT Finder® - a high-throughput screening platforms identifying novel T-cell targets, and TIL expansion platform StemTexp® that preferentially enriches TCM and TSCM populations of TIL. The company is currently developing potentially best-in-class gene-engineered TIL therapy based on these platforms.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
China
1
Frequently asked questions
Who invested in Grit Biotechnology?
Grit Biotechnology has 1 investors on record on gritt.io, 1 mid-stage.
When did Grit Biotechnology last raise funding?
The most recent investment in Grit Biotechnology recorded on gritt.io was in August 2023.
When was Grit Biotechnology founded?
Grit Biotechnology was founded in 2019.
What industry is Grit Biotechnology in?
Grit Biotechnology operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Grit Biotechnology based?
Grit Biotechnology is headquartered in Pudong New Area, Shanghai, China.